Vancouver, British Columbia – BioMark Diagnostics Inc. (“BioMark” or the “Company”) ($BUX:CSE) FSE: 20B) is pleased to announce that shares of the Company have commenced trading on the OTC Pink Sheets under the symbol BMKDF.
Rashid Ahmed, President and CEO states: “This is the just the first step towards developing a shareholder base in the United States. The Company is fully reporting in Canada and is listed on the Canadian Securities Exchange as well as on the Frankfurt Stock Exchange. These multiple listings & quotation platforms will allow us to access a significantly larger base of interested American biopharma investors, providing enhanced liquidity and better valuation. We are delighted to work with Merriman Capital Inc., whose hard work and effort has allowed us to obtain our US trading symbol. The Company’s capital markets team will work to ensure that the Company meets additional requirements and take BioMark to the next level.”
About Merriman Capital, Inc.
Merriman Capital, Inc. is an investment banking firm providing equity and options execution services, market making, and differentiated research for high growth companies. The firm also provides capital raising, advisory, and M&A services. Merriman Capital, Inc. is a wholly owned subsidiary of Merriman Holdings, Inc. ($MERR:OTCQX) and is the leading investment banking firm for OTCQX companies. For more information, please go to http://www.merrimanco.com/.
Merriman Capital, Inc. is a registered broker-dealer and member of The Financial Industry Regulatory Authority (FINRA) http://www.finra.org/ and the Securities Investor Protection Corporation (SIPC) http://www.sipc.org/.
About BioMark Diagnostics Inc.
BioMark is developing a proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.
For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer